ClinicalTrials.gg
CompletedNCT01470599Updated Oct 16, 2017Results posted

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

A Phase 2 interventional study of CP-690,550 and CP-690,550 in Crohn's Disease, sponsored by Pfizer. Completed at 75 sites in 17 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2017-10-16.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.

Enrollment
7th of 11
150 · median 180
Started
2012
with 1 other
Phase 2
9 of 17
none open now
Registered
9th of 17
by date

Among the 17 studies in Crohn Disease by Pfizer, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 2, and was the 9th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Crohn Disease by Pfizer as a file.
02

Study summary

The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who complete 26-week maintenance treatment of the A3921084 study or subjects who withdraw early due to A3921084 study treatment failure (see Appendix 5).
  • Women of must test negative for pregnancy prior to study enrolment.
  • Sexually active females of childbearing potential are required to use adequate methods during the study period and until completion of the follow-up procedures. No specific contraceptive measures are required in male subjects during study participation.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have been discontinued due to protocol violation(s) (as determined by the Sponsor) in the A3921084 study.
  • Subjects who were discontinued from the A3921084 study due to an adverse event.
  • Subjects likely to require any non-elective surgery or surgery requiring overnight stay (with the exception of minor same day outpatient procedures that will not interfere with study drug dosing).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    5mg BID

    Drug: CP-690,550

  • Experimental
    10mg BID

    Drug: CP-690,550

Interventions

06

What researchers measure

Primary outcomes

  1. Adjudicated Potential Cardiovascular Events

    Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium 'Standardized Definitions for End Point Events in Cardiovascular Trials' published October 2010.

    Time frame: From baseline to Week 52

  2. Adjudicated Malignancy Events

    Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.

    Time frame: From baseline to Week 52

  3. Adjudicated Hepatic Injury Events

    Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of clinical, safety \& laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy's law case, recovery \& liver failure (all yes, no or undetermined).

    Time frame: From baseline to Week 52

  4. Adjudicated Opportunistic Infection Events

    Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of SAE listings for serious infections coded to MedDRA infections \& infestations SOC \&/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research \& Treatment of Cancer/Invasive Fungal Infections Cooperative Group \& the National Institute of Allergy \& Infectious Diseases Mycoses Study Group \[EORTC/MSG\] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial \& parasitic infections \& vaccine dissemination) \& special interest infections (actinomycosis, Legionella \& mononucleosis-like toxoplasmosis).

    Time frame: From baseline to Week 52

  5. Adjudicated Gastrointestinal (GI) Perforation Events

    Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.

    Time frame: From baseline to Week 52

  6. Adjudicated Interstitial Lung Disease (ILD) Events

    Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety \& laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Percentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (\<) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.

    Time frame: Week 48

  2. Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.

    Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up

  3. Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.

    Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up

  4. Time to Relapse Among Participants in Clinical Remission at Baseline

    Relapse was defined as an increase in CDAI of more than (\>) 100 points from the baseline and an absolute CDAI score of \>220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves. n = number of participants remaining at risk.

    Time frame: From baseline to Week 52

  5. Observed CDAI Score by Week

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.

    Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up

  6. Change From Baseline Observed CDAI Score by Week

    CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.

    Time frame: Weeks 8, 16, 24, 36, 48 and 52/follow-up

  7. Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline

    Steroid-free clinical remission at Week 48 was a CDAI \<150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

    Time frame: Week 48

  8. Corticosteroid Use Over Time

    Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.

    Time frame: Weeks 8, 16, 24, 36 and 48

  9. Percentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit

    There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.

    Time frame: From baseline to Week 48

  10. Observed Change From Baseline in Fecal Calprotectin by Week

    Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.

    Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up

  11. Observed Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.

    Time frame: Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up

  12. Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit

    The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.

    Time frame: Baseline and Week 48/early termination (ET)

  13. Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit

    The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.

    Time frame: Baseline and Week 48/ET

  14. Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit

    The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.

    Time frame: Week 48/ET

  15. Percentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category

    The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.

    Time frame: Week 48/ET visit

  16. Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit

    The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.

    Time frame: Baseline and Week 48/ET visit

  17. Change From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit

    The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.

    Time frame: Baseline and Week 48/ET visit

  18. EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit

    EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.

    Time frame: Baseline and Week 48/ET visit

  19. Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit

    EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.

    Time frame: Baseline and Week 48/ET visit

  20. EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit

    EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.

    Time frame: Baseline and Week 48/ET visit

  21. Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit

    EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline and Week 48/ET visit

  22. Percentage of Participants Hospitalized Due to Crohn's Disease

    The number of participants hospitalized due to Crohn's disease were recorded at every study visit.

    Time frame: From baseline to Week 52/follow-up

  23. Length of Hospitalizations Due to Crohn's Disease

    The length of hospitalizations due to Crohn's disease were recorded at every study visit.

    Time frame: From baseline to Week 52/follow-up

07

Results

Posted Oct 16, 2017

Participant flow

This study was conducted in participants who completed the 26-week maintenance treatment of Study A3921084 or who withdrew early due to A3921084 study treatment failure according to prespecified criteria.

Participant flow — Overall Study
MilestoneTofacitinib 5 mg BIDTofacitinib 10 mg BID
Started6288
Completed4345
Not completed1943
Withdrew: Did not meet entrance criteria10
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject34
Withdrew: Other10
Withdrew: Protocol violation31
Withdrew: Adverse event related to study drug25
Withdrew: Insufficient clinical response627
Withdrew: Adverse event not related to study drug15

Outcome measures

PrimaryAdjudicated Potential Cardiovascular Events

Pre-specified cardiovascular events were adjudicated by committees of external experts who were blinded to treatment assignment. Potential events of interest (pEoI) were identified by the investigator, sponsor, review of alerts from central electrocardiogram assessments, and by search of adverse events (AE)/serious adverse event (SAE) listings for events coded to death (coronary and non-coronary), myocardial infarction (non-fatal), all coronary revascularization, unstable angina, stroke (fatal and non-fatal), transient ischemic attack, congestive heart failure, peripheral arterial vascular disease, dyspnoea, and chest pain. The independent reviewers (IRs) determined if the pEoI met the criteria for EoI classification according to the definitions summarized from the Clinical Data Interchange Standards Consortium 'Standardized Definitions for End Point Events in Cardiovascular Trials' published October 2010.

Time frame:
From baseline to Week 52
Reported as:
Number · Number of events meeting criteria
Adjudicated Potential Cardiovascular Events
Number of events meeting criteriaTofacitinib 5 mg BIDTofacitinib 10 mg BID
Adjudicated Potential Cardiovascular Events—0
PrimaryAdjudicated Malignancy Events

Pre-specified malignancy events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by the investigator, sponsor, potential primary event notifications (i.e. malignancies excluding non-melanoma skin cancers) for a specific protocol, events submitted for histopathology review for potential malignancies which met the criteria for potential malignancies, and by search of AE/SAE listings for events coded to Malignant tumors Standard Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQ) (20000194). IRs determined if the pEoI met the criteria for EoI classification according to the International Classification of Diseases for Oncology, a ten-digit multi-axial classification of the site (4 characters), morphology (4 digits), behavior (1 digit), and grading (1 digit) of neoplasms.

Time frame:
From baseline to Week 52
Reported as:
Number · Number of events meeting criteria
Adjudicated Malignancy Events
Number of events meeting criteriaTofacitinib 5 mg BIDTofacitinib 10 mg BID
Adjudicated Malignancy Events01
SecondaryPercentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of less than (\<) 150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95 percent (%) Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.

Time frame:
Week 48
Reported as:
Number · Percent
Percentage of Participants in Clinical Remission and Sustained Clinical Remission at Week 48
PercentTofacitinib 5 mg BIDTofacitinib 10 mg BID
Clinical remission (n=33, 36)87.88 (71.80 to 96.60)55.56 (38.10 to 72.06)
Sustained clinical remission (n=32, 35)75.00 (56.60 to 88.54)34.29 (19.13 to 52.21)
SecondaryPercentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.

Time frame:
Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Remission at Baseline of This Study
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Clinical remission: Baseline (n=61, 4)100.00 (94.13 to 100.00)100.00 (39.76 to 100.00)
Clinical remission: Week 8 (n=53, 4)75.47 (61.72 to 86.24)50.00 (6.76 to 93.24)
Clinical remission: Week 16 (n=52, 4)84.62 (71.92 to 93.12)75.00 (19.41 to 99.37)
Clinical remission: Week 24 (n=48, 4)85.42 (72.24 to 93.93)25.00 (0.63 to 80.59)
Clinical remission: Week 36 (n=40, 3)92.50 (79.61 to 98.43)33.33 (0.84 to 90.57)
Clinical remission: Week 48 (n=32, 3)87.50 (71.01 to 96.49)100.00 (29.24 to 100.00)
Clinical remission: Week 52/follow-up (n=37, 3)64.86 (47.46 to 79.79)33.33 (0.84 to 90.57)
Sustained clinical remission (n=31, 3)77.42 (58.90 to 90.41)33.33 (0.84 to 90.57)
SecondaryPercentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Clinical remission was defined as a CDAI score of \<150. Sustained clinical remission was defined as being in clinical remission (CDAI score \<150) at both Week 24 and Week 48. Clinical response was defined as a CDAI score reduction of at least 100 points from the A3921083 study baseline value. 95% Clopper-Pearson exact confidence interval reported for the proportions. n = number of participants with non-missing data.

Time frame:
Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Reported as:
Number · Percentage of participants
Percentage of Participants in Clinical Remission and Sustained Clinical Remission Among Participants in Clinical Response (CDAI-100 Response) or Clinical Remission at Baseline of This Study
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Clinical remission: Baseline (n=62, 23)98.39 (91.34 to 99.96)17.39 (4.95 to 38.78)
Clinical remission: Week 8 (n=54, 20)75.93 (62.36 to 86.51)35.00 (15.39 to 59.22)
Clinical remission: Week 16 (n=53, 19)84.91 (72.41 to 93.25)36.84 (16.29 to 61.64)
Clinical remission: Week 24 (n=49, 16)83.67 (70.34 to 92.68)43.75 (19.75 to 70.12)
Clinical remission: Week 36 (n=41, 13)90.24 (76.87 to 97.28)38.46 (13.86 to 68.42)
Clinical remission: Week 48 (n=33, 10)87.88 (71.80 to 96.60)50.00 (18.71 to 81.29)
Clinical remission: Week 52/follow-up (n=38, 12)65.79 (48.65 to 80.37)41.67 (15.17 to 72.33)
Sustained clinical remission (n=32, 10)75.00 (56.60 to 88.54)30.00 (6.67 to 62.25)
SecondaryTime to Relapse Among Participants in Clinical Remission at Baseline

Relapse was defined as an increase in CDAI of more than (\>) 100 points from the baseline and an absolute CDAI score of \>220 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. Data presented are rates estimated from Kaplan-Meier curves. n = number of participants remaining at risk.

Time frame:
From baseline to Week 52
Reported as:
Number · Percentage of participants
Time to Relapse Among Participants in Clinical Remission at Baseline
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 8 (n=55, 4)6.78 (3.38 to 11.78)NA (NA to NA)
Week 16 (n=51, 3)11.86 (7.15 to 17.87)25.00 (4.56 to 53.66)
Week 24 (n=46, 3)15.46 (9.98 to 22.05)25.00 (4.56 to 53.66)
Week 36 (n=38, 3)21.42 (14.82 to 28.83)25.00 (4.56 to 53.66)
Week 48 (n=7, 0)24.69 (17.21 to 32.89)NA (NA to NA)
SecondaryObserved CDAI Score by Week

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants remaining at risk.

Time frame:
Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Reported as:
Mean · Score on a scale
Observed CDAI Score by Week
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
Baseline (n=62, 88)77.13 ± 43.22291.19 ± 95.78
Week 8 (n=54, 75)105.39 ± 75.82176.96 ± 82.39
Week 16 (n=53, 66)86.58 ± 65.23178.94 ± 72.25
Week 24 (n=49, 59)85.12 ± 56.67163.66 ± 79.73
Week 36 (n=41, 48)73.34 ± 59.52158.67 ± 89.15
Week 48 (n=33, 36)73.91 ± 70.23154.11 ± 71.47
Week 52/Follow-up (n=38, 43)129.32 ± 114.82180.65 ± 98.80
SecondaryChange From Baseline Observed CDAI Score by Week

CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity. n = number of participants with non-missing data.

Time frame:
Weeks 8, 16, 24, 36, 48 and 52/follow-up
Reported as:
Mean · Score on a scale
Change From Baseline Observed CDAI Score by Week
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 8 (n=54, 75)26.96 ± 62.68-114.31 ± 112.44
Week 16 (n=53, 66)11.72 ± 52.25-112.02 ± 111.09
Week 24 (n=49, 59)6.33 ± 44.48-122.69 ± 117.65
Week 36 (n=41, 48)-10.78 ± 40.35-139.81 ± 126.18
Week 48 (n=33, 36)-4.79 ± 60.09-121.94 ± 129.21
Week 52/Follow-up (n=38, 43)47.66 ± 109.73-107.42 ± 119.05
SecondaryPercentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline

Steroid-free clinical remission at Week 48 was a CDAI \<150 points in participants who were steroid-free at Week 48. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, intensity of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 48 - Among Subjects on Steroids at A3921086 Baseline50.00 (1.26 to 98.74)9.09 (0.23 to 41.28)
SecondaryCorticosteroid Use Over Time

Use of corticosteroids (yes or no) was recorded at baseline and throughout the study. Percentage of participants taking corticosteriod at each visit was reported.

Time frame:
Weeks 8, 16, 24, 36 and 48
Reported as:
Number · Percentage of participants
Corticosteroid Use Over Time
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Baseline1.6120.45
Week 84.8421.59
Week 164.8413.64
Week 244.8412.50
Week 363.2310.23
Week 481.617.95
SecondaryPercentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit

There was a single study treatment dose adjustment allowed, at the discretion of the Investigator, from 5 mg BID to 10 mg BID or from 10 mg BID to 5 mg BID, after the initial 8 weeks of fixed open label treatment and for the remaining treatment period of 40 weeks. Percentage of participants whose study treatment were switched from 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID after initial assignment was reported.

Time frame:
From baseline to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Switching From 5 mg BID to 10 mg BID or 10 mg BID to 5 mg BID After Initial Assignment by Visit
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Baseline0 (0.00 to 5.78)0 (0.00 to 4.11)
Week 825.81 (15.53 to 38.50)0 (0.00 to 4.11)
Week 166.45 (1.79 to 15.70)0 (0.00 to 4.11)
Week 243.23 (0.39 to 11.71)2.27 (0.28 to 7.97)
Week 360 (0.00 to 5.78)1.14 (0.03 to 6.17)
Week 480 (0.00 to 5.78)0 (0.00 to 4.11)
SecondaryObserved Change From Baseline in Fecal Calprotectin by Week

Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation. n = number of participants with non-missing data.

Time frame:
Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Reported as:
Mean · mg per kilogram (mg/kg)
Observed Change From Baseline in Fecal Calprotectin by Week
mg per kilogram (mg/kg)Tofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 8 (n=53, 71)-105.51 ± 436.41-102.82 ± 310.10
Week 16 (n=54, 64)-144.65 ± 423.20-35.28 ± 718.82
Week 24 (n=49, 55)-120.49 ± 511.49-130.68 ± 337.23
Week 36 (n=41, 42)-169.92 ± 354.30-133.82 ± 364.51
Week 48 (n=37, 38)-189.61 ± 462.61-123.87 ± 376.70
Week 52/Follow-up (n=48, 57)-51.33 ± 453.73-109.23 ± 389.54
SecondaryObserved Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. n = number of participants with non-missing data.

Time frame:
Baseline and Weeks 8, 16, 24, 36, 48 and 52/follow-up
Reported as:
Mean · mg per liter (mg/L)
Observed Change From Baseline in High Sensitivity C-reactive Protein (CRP) by Week
mg per liter (mg/L)Tofacitinib 5 mg BIDTofacitinib 10 mg BID
Week 8 (n=61, 82)-0.44 ± 14.78-4.81 ± 26.76
Week 16 (n=58, 72)-2.46 ± 14.54-7.96 ± 25.11
Week 24 (n=54, 61)-2.76 ± 17.59-9.26 ± 30.20
Week 36 (n=46, 51)-4.42 ± 22.29-12.09 ± 30.61
Week 48 (n=43, 44)-4.55 ± 17.81-11.45 ± 31.30
Week 52/Follow-up (n=54, 71)3.86 ± 21.57-4.72 ± 31.34
SecondaryInflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit

The IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QoL) in participants with inflammatory bowel disease (IBD). IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL. n = number of participants with non-missing data.

Time frame:
Baseline and Week 48/early termination (ET)
Reported as:
Mean · Score on a scale
Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Baseline and Week 48/ET Visit
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
IBDQ Total Score, Baseline (n=62, 87)187.23 ± 20.38127.32 ± 34.17
IBDQ Total Score, Week 48/ET (n=57, 83)179.26 ± 29.89144.42 ± 42.16
Bowel Function Score, Baseline (n=62, 87)58.56 ± 6.8640.71 ± 9.90
Bowel Function Score, Week 48/ET (n=57, 83)55.70 ± 9.8246.70 ± 12.38
Emotional Status Score, Baseline (n=62, 87)69.68 ± 8.5848.61 ± 14.42
Emotional Status Score, Week 48/ET (n=57, 83)66.98 ± 12.2753.19 ± 17.32
Systemic Symptoms Score, Baseline (n=62, 87)26.95 ± 5.3617.20 ± 5.55
Systemic Symptoms Score, Week 48/ET (n=57, 83)25.82 ± 6.2820.35 ± 7.07
Social Function Score, Baseline (n=62, 87)32.03 ± 3.5920.80 ± 8.96
Social Function Score, Week 48/ET (n=57, 83)30.75 ± 5.1724.18 ± 8.98
SecondaryChange From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit

The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items are grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: bowel symptoms 10 to 70; systemic symptoms 5 to 35; emotional function 12 to 84; social function 5 to 35. For each domain, a higher score indicates better QoL. Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. Positive change in total score indicated improvement in QoL.

Time frame:
Baseline and Week 48/ET
Reported as:
Mean · Score on a scale
Change From Baseline IBDQ Total Score and Domain Scores (Bowel Function, Emotional Status, Systemic Symptoms, and Social Function) at Week 48/ET Visit
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
IBDQ Total Score, Week 48/ET-7.98 ± 24.9318.84 ± 40.45
Bowel Function Score, Week 48/ET-2.72 ± 8.306.37 ± 12.41
Emotional Status Score, Week 48/ET-3.07 ± 10.485.36 ± 15.00
Systemic Symptoms Score, Week 48/ET-1.00 ± 4.833.45 ± 7.43
Social Function Score, Week 48/ET-1.19 ± 4.243.66 ± 8.89
SecondaryPercentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit

The IBDQ is a psychometrically validated PRO instrument for measuring disease-specific QoL in participants with IBD. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, and ranged from 32 to 224 with a higher score indicating a better QoL. A score ≥170 corresponds to clinical remission. 95% Clopper-Pearson exact confidence interval reported for the proportions.

Time frame:
Week 48/ET
Reported as:
Number · Percentage of participants
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants With an IBDQ Total Score of Greater Than or Equal to (≥) 170 at Week 48/ET Visit70.18 (56.60 to 81.57)31.33 (21.59 to 42.44)
SecondaryPercentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category

The IBD PRTI modified questionnaire comprises 3 individual questions administered to the participant: participant satisfaction with study treatment; participant preference for study drug over prior treatment (this question on participant preference for study drug is prefaced by a simple question of previous treatment/s for IBD received in order to place the preference question into context) and participant willingness to reuse the study treatment again. Each of these questions (except the question on previous treatment, which is informational only) is scored on a 5 point Likert scale. PSA = Patient Satisfaction Assessment; PPTA = Patient Previous Treatment Assessment; PPA = Patient Preference Assessment; PWA = Patient Willingness Assessment.

Time frame:
Week 48/ET visit
Reported as:
Number · Percentage of participants
Percentage of Participants With a Response to the Patient-Reported Treatment Impact (PRTI) Assessment at Week 48/ET Visit by Category
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
PSA: Extremely dissatisfied00
PSA: Dissatisfied08.7
PSA: Neither satisfied nor dissatisfied017.4
PSA: Satisfied33.341.3
PSA: Extremely satisfied66.732.6
PPTA: Injectable prescription medicines40.532.6
PPTA: Prescription medicines taken by mouth45.243.5
PPTA: Surgery2.40
PPTA: Prescription medicines & surgery7.113.0
PPTA: No treatment4.810.9
PPA: Definitely prefer the drug I am receiving now88.156.5
PPA: Slight preference for drug I'm receiving now4.821.7
PPA: I have no preference either way7.117.4
PPA: Slight preference for previous treatment04.3
PPA: No, I definitely prefer my previous treatment00
PWA: Would definitely want to use same drug again83.360.9
PWA: Might want to use the same drug again14.323.9
PWA: I am not sure2.410.9
PWA: Might not want to use same drug again00
PWA: Definitely not want to use same drug again04.3
SecondaryShort Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit

The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.

Time frame:
Baseline and Week 48/ET visit
Reported as:
Mean · Score on a scale
Short Form 36 Health Survey (SF-36) Component and Domain Scores at Baseline and Week 48/ET Visit
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
Physical component score, Baseline (n=62, 86)50.15 ± 6.7337.80 ± 9.53
Physical component score, Week 48/ET (n=57, 83)48.43 ± 8.2241.87 ± 10.06
Mental Component Score, Baseline (n=62, 86)50.25 ± 9.1137.17 ± 11.94
Mental Component Score, Week 48/ET (n=57, 83)48.79 ± 10.6439.60 ± 12.87
Physical Functioning Domain, Baseline (n=62, 86)53.35 ± 5.5043.50 ± 10.37
Physical Functioning Domain, Week 48/ET (n=57, 83)51.40 ± 8.5946.81 ± 10.22
Role Physical Domain, Baseline (n=62, 86)50.97 ± 8.2235.93 ± 11.30
Role Physical Domain, Week 48/ET (n=57, 83)49.38 ± 8.7840.04 ± 12.99
Bodily Pain Domain, Baseline (n=62, 87)51.32 ± 8.5535.31 ± 9.14
Bodily Pain Domain, Week 48/ET (n=57, 83)49.57 ± 10.3041.04 ± 12.69
General Health Domain, Baseline (n=62, 87)41.60 ± 9.5131.74 ± 8.41
General Health Domain, Week 48/ET (n=57, 83)40.39 ± 10.0833.45 ± 10.16
Vitality Domain, Baseline (n=62, 87)52.78 ± 10.6836.92 ± 9.88
Vitality Domain, Week 48/ET (n=57, 83)51.06 ± 11.3841.03 ± 12.38
Social Functioning Domain, Baseline (n=62, 87)51.81 ± 7.2136.38 ± 12.29
Social Functioning Domain, Week 48/ET (n=57, 83)49.42 ± 9.6439.82 ± 13.39
Role Emotional Domain, Baseline (n=62, 86)50.12 ± 8.8538.55 ± 12.73
Role Emotional Domain, Week 48/ET (n=57, 83)47.97 ± 10.7841.13 ± 13.15
Mental Health Domain, Baseline (n=62, 87)49.89 ± 9.8437.61 ± 11.98
Mental Health Domain, Week 48/ET (n=57, 83)49.24 ± 10.2740.13 ± 12.52
SecondaryChange From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit

The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based T scores for both the SF36 version 2 and SF36 health domain scales and component summary measures have means of 50 and standard deviations of 10. Higher scores indicate better health-related QoL. n = number of participants with non-missing data.

Time frame:
Baseline and Week 48/ET visit
Reported as:
Mean · Score on a scale
Change From Baseline SF-36 Component and Domain Scores at Week 48/ET Visit
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
Physical component score, Week 48/ET (n=57, 83)-1.47 ± 7.174.47 ± 11.06
Mental Component Score, Week 48/ET (n=57, 83)-1.88 ± 9.053.07 ± 11.53
Physical Functioning Domain, Week 48/ET (n=57, 83)-1.80 ± 7.503.49 ± 10.74
Role Physical Domain, Week 48/ET (n=57, 83)-1.38 ± 7.874.60 ± 12.62
Bodily Pain Domain, Week 48/ET (n=57, 83)-1.60 ± 7.906.15 ± 12.92
General Health Domain, Week 48/ET (n=57, 83)-1.42 ± 10.002.25 ± 7.99
Vitality Domain, Week 48/ET (n=57, 83)-1.63 ± 10.394.47 ± 12.16
Social Functioning Domain, Week 48/ET (n=57, 83)-2.92 ± 9.093.69 ± 13.46
Role Emotional Domain, Week 48/ET (n=57, 82)-2.26 ± 10.293.28 ± 11.38
Mental Health Domain, Week 48/ET (n=57, 83)-1.02 ± 8.632.87 ± 11.72
SecondaryEuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit

EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state. n = number of participants with non-missing data.

Time frame:
Baseline and Week 48/ET visit
Reported as:
Mean · Score on a scale
EuroQoL 5 Dimensions Questionnaire (EQ-5D) Utility Scores at Baseline and Week 48/ET Visit
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
Utility Score, Baseline (n=62, 85)0.85 ± 0.210.57 ± 0.28
Utility Score, Week 48/ET (n=57, 83)0.84 ± 0.160.66 ± 0.31
SecondaryChange From Baseline EQ-5D Utility Scores at Week 48/ET Visit

EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, selfcare, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range from 0.594 to 1.000; a higher score indicates a better health state.

Time frame:
Baseline and Week 48/ET visit
Reported as:
Mean · Score on a scale
Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit
Score on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BID
Change From Baseline EQ-5D Utility Scores at Week 48/ET Visit-0.02 ± 0.210.10 ± 0.36
SecondaryEQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit

EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeters (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. n = number of participants with non-missing data.

Time frame:
Baseline and Week 48/ET visit
Reported as:
Mean · mm
EQ-5D Visual Analogue Scale (VAS) Scores at Baseline and Week 8/ET Visit
mmTofacitinib 5 mg BIDTofacitinib 10 mg BID
VAS Score, Baseline (n=62, 86)77.98 ± 16.1848.60 ± 19.21
VAS Score, Week 48/ET (n=57, 83)73.40 ± 18.5457.60 ± 24.60
SecondaryChange From Baseline EQ-5D VAS Scores at Week 8/ET Visit

EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline and Week 48/ET visit
Reported as:
Mean · mm
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit
mmTofacitinib 5 mg BIDTofacitinib 10 mg BID
Change From Baseline EQ-5D VAS Scores at Week 8/ET Visit-3.79 ± 20.5610.16 ± 26.57
SecondaryPercentage of Participants Hospitalized Due to Crohn's Disease

The number of participants hospitalized due to Crohn's disease were recorded at every study visit.

Time frame:
From baseline to Week 52/follow-up
Reported as:
Number · Percentage of participants
Percentage of Participants Hospitalized Due to Crohn's Disease
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BID
Percentage of Participants Hospitalized Due to Crohn's Disease11.315.9
PrimaryAdjudicated Hepatic Injury Events

Pre-specified liver injury events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of clinical, safety \& laboratory databases (potential Hy's law event, ALT/AST ≥5 x ULN, events meeting hepatic discontinuation criteria, SAEs coded to MedDRA hepatobiliary system organ class (SOC), AEs/SAEs coded to MedDRA liver infections or infectious biliary disorders SMQ, AEs coded to MedDRA drug-induced liver injury (DILI) preferred term or any death with ALT or AST ≥3xULN, bilirubin ≥2xULN or jaundice). IRs determined if the pEoI met the criteria for EoI classification by assessing DILI (definite, highly likely, probable, possible, unlikely, unrelated or undetermined), pattern (hepatocellular, mixed, cholestatic or undetermined), likely, competing or alternative cause(s), severity (mild, moderate, severe, fatal/transplantation or undetermined), Hy's law case, recovery \& liver failure (all yes, no or undetermined).

Time frame:
From baseline to Week 52
Reported as:
Number · Number of events meeting criteria
Adjudicated Hepatic Injury Events
Number of events meeting criteriaTofacitinib 5 mg BIDTofacitinib 10 mg BID
Adjudicated Hepatic Injury Events—0
PrimaryAdjudicated Opportunistic Infection Events

Pre-specified opportunistic infection events were adjudicated by blinded committees of external experts. pEoI were identified by investigator, sponsor \& search of SAE listings for serious infections coded to MedDRA infections \& infestations SOC \&/or events meeting pre-specified criteria for IR pre-screening to determine if adjudication is required. IRs determined if the pEoI met the criteria for EoI classification according to definitions for opportunistic infections (invasive fungal infections per the European Organization for Research \& Treatment of Cancer/Invasive Fungal Infections Cooperative Group \& the National Institute of Allergy \& Infectious Diseases Mycoses Study Group \[EORTC/MSG\] Consensus Group definitions, endemic fungal infections per the EORTC/MSG Consensus Group definitions, other fungal infections, viral, bacterial \& parasitic infections \& vaccine dissemination) \& special interest infections (actinomycosis, Legionella \& mononucleosis-like toxoplasmosis).

Time frame:
From baseline to Week 52
Reported as:
Number · Number of events meeting criteria
Adjudicated Opportunistic Infection Events
Number of events meeting criteriaTofacitinib 5 mg BIDTofacitinib 10 mg BID
Adjudicated Opportunistic Infection Events11
PrimaryAdjudicated Gastrointestinal (GI) Perforation Events

Pre-specified GI perforation events were adjudicated by committees of external experts who were blinded to treatment assignment. The pEoI were identified via search of AE/SAE listings using the MedDRA GI Perforation SMQ. The IRs determined if the pEoI met the criteria for EoI classification based on whether a GI perforation occurred and if yes, the location within the GI tract, possible contributing medical conditions and/or concomitant medications.

Time frame:
From baseline to Week 52
Reported as:
Number · Number of events meeting criteria
Adjudicated Gastrointestinal (GI) Perforation Events
Number of events meeting criteriaTofacitinib 5 mg BIDTofacitinib 10 mg BID
Adjudicated Gastrointestinal (GI) Perforation Events—2
PrimaryAdjudicated Interstitial Lung Disease (ILD) Events

Pre-specified ILD events were adjudicated by committees of external experts who were blinded to treatment assignment. pEoI were identified by searches of the clinical, safety \& laboratory databases (AEs coded to the MedDRA ILD SMQ and events nominated by the study clinician or clinical lead). The IRs determined if the pEoI met the criteria for EoI classification by assessment of the ILD event (probably ILD, possible ILD, alternative diagnosis likely, other or insufficient information to classify).

Time frame:
From baseline to Week 52

No measurements were reported for this outcome.

SecondaryLength of Hospitalizations Due to Crohn's Disease

The length of hospitalizations due to Crohn's disease were recorded at every study visit.

Time frame:
From baseline to Week 52/follow-up
Reported as:
Number · Percentage of participnats
Length of Hospitalizations Due to Crohn's Disease
Percentage of participnatsTofacitinib 5 mg BIDTofacitinib 10 mg BID
<3 days1.62.3
3 to 6 days6.510.2
7 to 10 days03.4
> 10 days03.4

Adverse events

Collected over SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5 mg BID—5/62 (8.1%)42/62 (67.7%)
Tofacitinib 10 mg BID—14/88 (15.9%)58/88 (65.9%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BID
Crohn's diseaseGastrointestinal disorders3/627/88
Small intestinal obstructionGastrointestinal disorders0/622/88
Colon dysplasiaGastrointestinal disorders1/620/88
Chest painGeneral disorders1/620/88
Influenza like illnessGeneral disorders1/620/88
Diarrhoea infectiousInfections and infestations1/620/88
PyelonephritisInfections and infestations1/620/88
Acute kidney injuryRenal and urinary disorders1/620/88
DyspnoeaRespiratory, thoracic and mediastinal disorders1/620/88
HyperhidrosisSkin and subcutaneous tissue disorders1/620/88
Most frequent other events
Showing 10 of 65
Most frequent other events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BID
Crohn's diseaseGastrointestinal disorders19/6211/88
NasopharyngitisInfections and infestations8/627/88
Urinary tract infectionInfections and infestations8/627/88
Abdominal painGastrointestinal disorders7/627/88
GastroenteritisInfections and infestations7/622/88
NauseaGastrointestinal disorders2/629/88
influenzaInfections and infestations5/628/88
ArthralgiaMusculoskeletal and connective tissue disorders5/628/88
VomitingGastrointestinal disorders1/626/88
PyrexiaGeneral disorders1/626/88

Baseline characteristics

The safety analysis set (SAS) consisted of all participants enrolled in this open label (OL) extension study who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(Years)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
Mean41.0 ± 12.638.2 ± 11.639.4 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTotal
Female304171
Male324779
08

Study locations

75 sites
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • Clinical Research Of The Rockies
    Lafayette, Colorado 80026, United States
  • Gastroenterology Consultants of Clearwater
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center
    Clearwater, Florida 33756, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Shands Endoscopy Center
    Gainesville, Florida 32608, United States
  • Shands Hospital at the University of Florida
    Gainesville, Florida 32610-0214, United States
  • Investigational Drug Service
    Gainesville, Florida 32610, United States
  • Shands Medical Plaza and Cancer Center
    Gainesville, Florida 32610, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Gulfshore Endoscopy Center (Endoscopies Only)
    Naples, Florida 34102, United States
  • North Florida Gastroenterology Research, LLC
    Orange Park, Florida 32073, United States
  • Internal Medicine Specialists
    Orlando, Florida 32806, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • East Ann Arbor Health and Geriatrics Center
    Ann Arbor, Michigan 48109-2701, United States
  • University of Michigan Health Systems
    Ann Arbor, Michigan 48109-5000, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Surgical Centers of Michigan
    Troy, Michigan 48098, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • NYU Langone Nassau Gastroenterology Associates
    Great Neck, New York 11021, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Great Lakes Gastroenterology
    Mentor, Ohio 44060, United States
  • The Endoscopy Center of Lake County
    Mentor, Ohio 44060, United States
  • Great Lakes Gastroenterology
    Willoughby, Ohio 44094, United States
  • Christus Trinity Mother Frances Endoscopy Center
    Tyler, Texas 75701, United States
  • Digestive Health Specialists of Tyler
    Tyler, Texas 75701, United States
  • Endoscopy Center of Tyler
    Tyler, Texas 75701, United States
  • University of Utah HSC
    Salt Lake City, Utah 84132, United States
  • Digestive and Liver Disease Specialists
    Norfolk, Virginia 23502, United States
  • Wisconsin Center for Advanced Research - GI Associates, LLC
    Milwaukee, Wisconsin 53215, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • GI Associates
    Wauwatosa, Wisconsin 53226, United States
  • Nepean Public Hospital
    Kingswood, New South Wales 2747, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • 4-MBAL, Parvo vatreshno otdelenie
    Sofia, 1000, Bulgaria
  • MBAL Sofiamed OOD, Otdelenie po gastroenterologia
    Sofia, 1797, Bulgaria
  • Office of Dr. David C Pearson
    Victoria, British Columbia V8R 6R3, Canada
  • Office of Drs. Ranjith Andrew Singh, Jamie D. Papp
    Victoria, British Columbia V8V 3P9, Canada
  • PerCuro Clinical Research Limited
    Victoria, British Columbia V8V 3P9, Canada
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
  • Montreal General Hospital-Mcgill University Health Centre
    Montreal, Quebec H3G 1A4, Canada
  • RDG centrum s.r.o.
    Hradec Kralove, 500 12, Czechia
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 50012, Czechia
  • Medial Pharma spol.s.r.o.
    Hradec Králové, 500 12, Czechia
  • Hopital Huriez - CHRU de Lille
    Lille Cedex, 59037, France
  • Hôpital Haut-Lévêque
    Pessac Cedex, 33604, France
  • Charite Universitaetsmedizin Berlin, Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89081, Germany
  • General Hospital of Athens "Evangelismos",1st Gastroenterology Department
    Kolonaki Athens, 106 76, Greece
  • Peterfy Sandor Utcai Korhaz, Rendelointezet es Baleseti Kozpont, I. sz. Belgyogyaszat
    Budapest, 1076, Hungary
  • Pannonia Magánorvosi Centrum Kft
    Budapest, 1136, Hungary
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
    Budapest, H-1125, Hungary
  • Bugat Pal Korhaz Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.,
    Gyongyos, 3200, Hungary
  • Clinfan Kft.
    Szekszard, 7100, Hungary
  • Department of medicine Shaare Zedek Medical Center
    Jerusalem, 91031, Israel
  • Dept. of Gastroenterology & Hepatology, Meir Medical Center
    Kfar Saba, 44281, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital
    Sapporo, Hokkaido 060-0033, Japan
  • The Hospital of Hyogo College of Medicine
    Nishinomiya, Hyogo 663-8501, Japan
  • National Hospital Organization Sendai Medical Center
    Sendai, Miyagi 983-8520, Japan
  • Toho University Sakura Medical Center
    Chiba, 285-8741, Japan
  • Osaka City University Hospital
    Osaka, 545-8586, Japan
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center
    Soeul, 138-736, Korea, Republic of
  • VU University Medical Center
    Amsterdam, 1081 HV, Netherlands
  • Academisch Medisch Centrum
    Amsterdam, 1105 AZ, Netherlands
  • Parklands Medical Centre
    Durban, 4091, South Africa
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario de La Princesa
    Madrid, 28006, Spain
  • Hospital Puerta de Hierro Majadahonda Servicio Digestivo - Planta 2
    Madrid, 28222, Spain
  • Municipal Institution "Odesa Regional Clinical Hospital". Odesa Regional Centre of Gastroenterology.
    Odesa, 65117, Ukraine
  • Medical Clinical Research Center of Medical Center "Health Clinic" LLC
    Vinnitsa, 21029, Ukraine
09

References and documents

Publications

  • Panes J, D'Haens GR, Higgins PDR, Mele L, Moscariello M, Chan G, Wang W, Niezychowski W, Su C, Maller E. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. Aliment Pharmacol Ther. 2019 Feb;49(3):265-276. doi: 10.1111/apt.15072. PubMed 30663107 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Jul 2016, 51 months.

Results were first posted in Oct 2017, 1 year 3 months after primary completion.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 51 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2011
First posted
Nov 11, 2011
StartActual
Apr 2012
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Oct 16, 2017
Last update
Oct 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01470599
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 11, 2011
Start date
Apr 2012
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Oct 16, 2017
Last update
Oct 16, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion